Insider trade

Officer sold ~$238K of EW shares in the open market

Traded Aug 28, 2026 · Filed Aug 28, 2026

Edwards LifesciencesEW

~$238K
Reported value · 2,644 sh @ $89.98: 18K
Holds after · shares reported: -5.6%
stock since the trade · S&P 500 -0.7%, $90.21 → $85.19 on Oct 1

Why it stands out

Edwards Lifesciences's CVP, EMEACLA sold $238K of Edwards Lifesciences shares. Nobody planned it ahead of time.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Aug 28, 2026
Reporting period: Not applicable
Filed with the SEC: Aug 28, 2026

Officer$100K–$500K

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$237,907

Shares × reported transaction price

Timing vs results

36 days after results of Jul 23, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $90.21 on Aug 28, 2026, 24% above its 52-week low and 5% below its high, after a 5% rise over the previous 30 trading days

52-week range $72.65 (Oct 16, 2025) to $95.18 (Jul 6, 2026), 78% of the way up, from 251 adjusted closes. 30 trading days earlier: $85.73 on Jul 17, 2026. Describes the past only, not a forecast

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

Securities lawsuit open at the trade date

A securities lawsuit naming the company as a defendant was filed on Oct 14, 2024 in the U.S. District Court, C.D. California. A filing is an allegation, not a finding.

Dhimant Patel v. Edwards Lifesciences Corporation, docket 8:24-cv-02221, via CourtListener (court records). Nature of suit 850, company named as first defendant